July 31 (Reuters) - Evolus ( EOLS ), an anti-wrinkle

injection maker, reported its first-ever quarterly profit on an

adjusted basis on Wednesday, driven by strong sales of its Botox

rival Jeuveau.

The company, which launched Jeuveau in 2019, has focused

on expanding the reach of its cosmetic treatment, particularly

targeting a younger demographic compared to other players who

typically focus on people in their 40s.

Evolus' ( EOLS ) earnings come a few days after Botox maker AbbVie ( ABBV )

noted a recovery in demand for its market-leading

cosmetic injection in the U.S. as inflation continued to ease.

The Newport Beach, California-based company recorded an

adjusted operating income of $1.1 million for the second

quarter. Two analysts, on average, had expected the company to

record a quarterly loss of $1.8 million, according to LSEG data.

Its sales were $66.9 million in the second quarter, up 36%

from last year and marginally ahead of the analysts' average

estimate of $65.8 million.

In comparison, AbbVie ( ABBV ), a significantly larger player,

reported a 6.4% increase in Botox cosmetic sales, totaling $729

million for the quarter.

"For us, we believe a majority, greater than 50% of the

users of Jeuveau are that younger generation. We also believe

that as we've entered, we've been able to expand the market and

that's why you're seeing this over indexing on growth in our

business," CEO David Moatazedi told Reuters in an interview.

He added that some of their customers are as young as in

their 20s.

The company added 770 new accounts during the quarter,

bringing its total to about 14,000 customers. About 70% of their

customers reorder, the company said.

Evolus ( EOLS ) has raised its full-year revenue forecast to a

range of $260 million to $270 million, up from an earlier range

of $255 million to $265 million. Last year, Evolus ( EOLS ) had recorded

$202.1 million in revenue.